

In the Claims

1-40 (canceled).

41 (currently amended). A monoclonal antibody selected from the group consisting of monoclonal antibody 16D10, having binding specificity for glycosylated bile salt dependent lipase (BSDL) or fetoacinar pancreatic protein (FAPP) and produced by the hybridoma deposited under the accession number I-3188 or, an antigen binding fragment or derivative thereof[[,]]; a derivative of the 16D10 antibody selected from a chimeric, humanized or single chain scFv antibody or a monoclonal antibody~~or an antibody~~ which essentially binds to the same epitope of the BSDL or FAPP protein as monoclonal antibody 16D10.

42 (currently amended). The monoclonal antibody according to claim 41, wherein said monoclonal antibody is humanized, chimeric or human.

43 (currently amended). The monoclonal antibody according to claim 41, wherein the monoclonal antibody is of the IgG type.

44 (currently amended). The monoclonal antibody according to claim 41, wherein the monoclonal antibody is a single chain antibody.

45 (currently amended). A kit for diagnosis of a pancreatic pathology, comprising a monoclonal antibody ~~selected from the monoclonal antibody 16D10, an antigen binding fragment or derivative thereof, or an antibody which essentially binds to the same epitope as monoclonal antibody 16D10,~~ according to claim 41 and ~~optionally~~ a means for detecting the immunological complex resulting from the immunological reaction between the biological sample and said antibody.

46 (withdrawn-currently amended). A method of detection *in vitro* of a subject suffering from a pancreatic pathology, comprising contacting a biological sample from the subject with ~~an~~

monoclonal antibody according to claim 41 and detecting the formation of immunological complexes resulting from the immunological reaction between said antibody and said biological sample; wherein said antibody:

—— a) —— can specifically recognize a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by one or more enzymes having ~~ose-~~transferase activity selected in the group consisting of Core 2 $\beta(1-6)$ N-acetylglucosaminyltransferase (C2GnT), fucosyltransferase FUT3 which has $\alpha(1-3)$ and $\alpha(1-4)$ fucosyltransferase activity, or fucosyltransferase FUT7 which has $\alpha(1-3)$ fucosyltransferase activity; or

—— b) —— is a monoclonal antibody selected from monoclonal antibody 16D10, an antigen binding fragment or derivative thereof, and an antibody which essentially binds to the same epitope as monoclonal antibody 16D10.

47-48 (canceled).

49 (withdrawn). The method according to claim 46, wherein said biological sample is a sample of pancreatic tissue.

50 (withdrawn). The method according to claim 46, wherein said biological sample is a biological fluid selected from pancreatic juices, serum or urine.

51 (withdrawn). The method according to claim 46, wherein the method enables the detection of a subject suffering from pancreatic cancer.

52-62 (canceled).

63 (new). The monoclonal antibody according to claim 42, wherein said monoclonal antibody is humanized.

64 (new). The monoclonal antibody according to claim 42, wherein said monoclonal antibody is chimeric.

65 (new). The monoclonal antibody according to claim 42, wherein said monoclonal antibody is human.

66 (new). The monoclonal antibody according to claim 41, wherein said monoclonal antibody is the 16D10 antibody, having binding specificity for glycosylated bile salt dependent lipase (BSDL) or fetoacinar pancreatic protein (FAPP) and produced by the hybridoma deposited under the accession number I-3188.

67 (new). The monoclonal antibody according to claim 41, wherein said monoclonal antibody is an antigen binding fragment of the 16D10 antibody.

68 (new). The monoclonal antibody according to claim 41, wherein said monoclonal antibody is a single chain scFv antibody.

69 (new). The monoclonal antibody according to claim 41, further comprising a label.

70 (new). A composition comprising a pharmaceutically acceptable excipient and a labeled or unlabeled monoclonal antibody selected from the group consisting of: monoclonal antibody 16D10, having binding specificity for glycosylated bile salt dependent lipase (BSDL) or fetoacinar pancreatic protein (FAPP) and produced by the hybridoma deposited under the accession number I-3188, or an antigen binding fragment thereof; a derivative of the 16D10 antibody selected from a chimeric, humanized or single chain scFv antibody; and a monoclonal antibody which essentially binds to the same epitope of the BSDL or FAPP protein as monoclonal antibody 16D10.

71 (new). The composition according to claim 70, wherein said labeled or unlabeled monoclonal antibody is humanized, chimeric or human.

72 (new). The composition according to claim 70, wherein the labeled or unlabeled monoclonal antibody is of the IgG type.

73 (new). The composition according to claim 70, wherein the labeled or unlabeled monoclonal antibody is a single chain antibody.

74 (new). The composition according to claim 71, wherein said labeled or unlabeled monoclonal antibody is humanized.

75 (new). The composition according to claim 71, wherein said labeled or unlabeled monoclonal antibody is chimeric.

76 (new). The composition according to claim 71, wherein said labeled or unlabeled monoclonal antibody is human.

77 (new). The composition according to claim 70, wherein said labeled or unlabeled monoclonal antibody is the 16D10 antibody, having binding specificity for glycosylated bile salt dependent lipase (BSDL) or human fetoacinar pancreatic protein (FAPP) and produced by the hybridoma deposited under the accession number I-3188.

78 (new). The composition according to claim 70, wherein said labeled or unlabeled monoclonal antibody is an antigen binding fragment of the 16D10 antibody.

79 (new). The composition according to claim 70, wherein said labeled or unlabeled monoclonal antibody is a single chain scFv antibody.

80 (new). A hybridoma producing the monoclonal antibody is the 16D10 antibody, said hybridoma deposited under the accession number I-3188 and said antibody having binding

specificity for glycosylated bile salt dependent lipase (BSDL) or fetoacinar pancreatic protein (FAPP).